Abstracts tagged "Myopathies"

Abstract Number: 1164 • ACR Convergence 2024
IVIG Treatment Duration in Immune-mediated Necrotizing Myopathy and a Possible Association of Vacuolar Changes with Black/African American Female Patients
Asim Mohamed¹, Liron Caplan² and Melissa Griffith³, ¹PGY5, Aurora, CO, ²Rocky Mountain Regional VAMC, Aurora, CO, ³University of Colorado, Aurora, CO
Background/Purpose: Immune Mediated Necrotizing Myopathy (IMNM) is a debilitating but understudied entity. Correlations of demographic and clinical features with pathological findings remain underexplored. In addition,…
Abstract Number: 2079 • ACR Convergence 2024
Understanding Relapse Patterns in Anti-HMGCR Statin-induced IMNM: A Detailed Comparative Study
Silvia Grazzini¹, Angeles Galindo-Feria², Edoardo Conticini¹, Ingrid Lundberg³ and Maryam Dastmalchi⁴, ¹Università di Siena, Siena, Italy, ²Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska University hospital, Stockholm, Sweden
Background/Purpose: Statin-induced immune-mediated necrotizing myopathy (IMNM) is a recently recognized subtype of idiopathic inflammatory myopathy (IIM). This condition is marked by the sudden onset of…
Abstract Number: 0333 • ACR Convergence 2024
Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease
shiri keret¹, Raisa Silva², Irada Choudhuri², Eugenia Gkiaouraki³, Tanya Chandra⁴, Nantakarn Pongtarakulpanit⁵, shreya Sriram³, silvia Martinez Laverde³, Dana Ascherman³, Siamak Mogahadam⁵, Chester Oddis⁵ and Rohit Aggarwal⁶, ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Lung involvement is the most common and severe extra-muscular manifestation of Idiopathic Inflammatory Myopathies (IIM). Early identification of patients at risk for lung transplant…
Abstract Number: 1167 • ACR Convergence 2024
Construction of a Refractory Myositis Predictive Index (ReMPI) in a Cohort of Patients with Idiopathic Inflammatory Myopathies
Andres Gaytan Garcia de Alba¹, Nancy R Mejía-Domínguez¹, Yatzil Reyna-Juárez¹, Beatriz Alcalá-Carmona¹, María José Ostos-prado¹, Agustin Hernandez Lopez¹, Diana Gomez-martin² and Jiram Torres Ruiz³, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, ²INCMNSZ, Mexico City, Federal District, Mexico, ³INCMNSZ, Mexico, Federal District, Mexico
Background/Purpose: An important proportion of patients with Idiopathic inflammatory myopathies (IIM) are at risk of developing refractory disease, which predispose them to cumulate damage, treatment…
Abstract Number: 2080 • ACR Convergence 2024
HLA-DRB1*11:01 Association Differenciates Anti-hmgcr Immune-mediated Necrotizing Myopathy from Non-immune Mediated Statin Myotoxicity
Cristina Corrales Selaya¹, Diana Prieto-Peña², gonzalo Ocejo-Viñals³, Carmen Secada Gómez⁴, alfonso Corrales-Martínez⁵, Carmen Ibarbia⁶, Zaida Salmón-gonzalez⁶, Marta Martín-millan⁶, Virginia Portilla-González⁶, Nerea mota-perez⁶, M. sebastian-mora gil⁶, J.C Batista-liz⁶, Veronica Pulito-Cueto⁷, Raquel Lopez-mejias⁷, Ricardo Blanco-Alonso⁸ and Jose Luis Hernandez⁶, ¹Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁶Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁷IDIVAL, Santander, Spain, ⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Genetic risk factors may explain why only a small proportion of patients taking statins develop severe cases of anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) immune-mediated necrotizing myopathy…
Abstract Number: 0337 • ACR Convergence 2024
Characterization of Statin Induced Myopathy in the Hospital Setting
Olivia Yang¹, KUMAR VENKAT², Jeffery Durbin³ and Scott Kubomoto¹, ¹Riverside Community Hospital, Riverside, CA, ²Voluntary Clinical Associate Professor of Medicine -UCRSOM, Riverside, California, IRVINE, CA, ³HCA Healthcare Physicians Services Group, Brentwood, TN
Background/Purpose: Adverse effects of statin use involve the muscle and related rhabdomyolysis. Known risk factors for rhabdomyolysis include female sex, older age, Asian race, hypothyroidism,…
Abstract Number: 1169 • ACR Convergence 2024
Efficacy of Intravenous Immunoglobulin (Octagam 10%) on Pulmonary Manifestations in Patients with Dermatomyositis: Results from the ProDERM Study
Rohit Aggarwal¹, christina Charles-Schoeman² and Joachim Schessl³, and the ProDERM Investigators, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ²UCLA Medical Center, Santa Monica, CA, ³Friedrch-Baur-Institut; Ludwig-Maximilians University of Munich, Munich, Germany
Background/Purpose: Interstitial lung disease (ILD) and other pulmonary manifestations are a major cause of mortality and morbidity in patients with dermatomyositis (DM). The ProDERM study…
Abstract Number: 2085 • ACR Convergence 2024
The Effects of Pioglitazone on Metabolic Dysregulation in Inclusion Body Myositis: An Open-Label Pilot Study
Brittany Adler¹, Michael Bene¹, Cissy Zhang², Julie Paik¹, Christopher Mecoli¹, Thomas Lloyd³, Eleni Tiniakou⁴, Erika Darrah¹, Lisa Christopher-Stine¹, Albert Mears¹, Megan McGowan¹, Ruben Pagkatipunan¹, Anne Le² and Jemima Albayda⁵, ¹Johns Hopkins University, Baltimore, MD, ²Gigantest, Baltimore, MD, ³Baylor College of Medicine, Houston, TX, ⁴Johns Hopkins University, Lutherville Timonium, MD, ⁵Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Inclusion body myositis (IBM) is a progressive muscle disease for which there is no effective treatment. Mitochondrial dysregulation is a pathologic hallmark of IBM.…
Abstract Number: 0341 • ACR Convergence 2024
Efficacy and Safety of Nintedanib in Patients with Idiopathic Inflammatory Myopathy-related Interstitial Lung Disease
Kaito Aoki¹, Keigo Shimura¹, Toshiki Ohisa¹, Akira Ishii¹, Mai Sugiyama², Yuichiro Ota¹, Ayumi Nishikawa³, Noriko Sasaki³, Chiho Yamada¹ and Shinji Sato², ¹Tokai University School of Medicine, Isehara, Japan, ²Tokai University, Isehara, Japan, ³Tokai University Hachioji Hospital, Hachioji, Japan
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are chronic inflammatory disorders that affect muscle, skin and lung to varying degrees. Interstitial lung disease (ILD) is a major…
Abstract Number: 1645 • ACR Convergence 2024
Antisynthetase Autoantibodies Disrupt the Function of Their Target Aminoacyl-tRNA Synthetases in Muscle Cells
Maria Casal-Dominguez¹, Iago Pinal-Fernandez², Sandra Muñoz-braceras³, Corinna preuße⁴, katherine Pak¹, Jiram Torres Ruiz⁵, Jon Musai¹, Stefania Dell'Orso⁶, Faiza Naz⁶, Shamima Islam², Gusatavo Gutierrez-Cruz², Albert Selva-O’Callaghan⁷, jose milisenda⁸, Werner Stenzel⁹ and Andrew Mammen², ¹National Institutes of health, Bethesda, MD, ²NIH, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Disease, Bethesda, MD, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁵INCMNSZ, Mexico, Federal District, Mexico, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁷Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁸Hospital Clinic de Barcelona, Barcelona, Spain, ⁹Charite University, Berlin, Germany
Background/Purpose: Antisynthetase syndrome (AS) is type of myositis characterized by autoantibodies targeting aminoacyl-transfer tRNA synthetases (aaRSs), the enzymes responsible for loading the appropriate amino acid…
Abstract Number: 2086 • ACR Convergence 2024
Specific Transcriptomic Profile Associated with Disease Activity in Muscle Biopsies from Patients with Sarcoid Myopathy
Iago Pinal-Fernandez¹, Nikolas Ruffer², Maria Casal-Dominguez³, katherine Pak⁴, Stefania Dell'Orso⁵, Faiza Naz⁵, Shamima Islam⁶, Gusatavo Gutierrez-Cruz⁶, Margherita Milone⁷, Albert selva-O'Callaghan⁸, jose milisenda⁹, Felix Kleefeld¹⁰, Andrew Mammen⁶, Teerin Liewluck¹¹ and Werner Stenzel¹², ¹NIAMS/National Institutes of Health, Bethesda, MD, ²Klinikum Bad Bramstedt, Hamburg, Germany, ³NIAMS, NIH, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁶NIH, Bethesda, MD, ⁷Mayo Clinic-Rochester, Rochester, MN, ⁸Systemic Autoimmune Disease Section, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁹Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁰Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany, Berlin, Germany, ¹¹Mayo Clinic, Rochester, MN, ¹²Charite University, Berlin, Germany
Background/Purpose: Sarcoidosis, a multisystem inflammatory disorder of unknown etiology, exhibits diverse clinical manifestations, with symptomatic musculoskeletal involvement being relatively uncommon but potentially debilitating. We conducted…
Abstract Number: 0343 • ACR Convergence 2024
An Interlaboratory Variability Study of Detection Methods for Myositis-Specific and Myositis-Associated Autoantibodies in Sera from Patients with Idiopathic Inflammatory Myopathies
Georgina Harvey¹, Idil Ashur², Xavier Bossuyt³, Martin Bluethner⁴, Anna Brusch⁵, Chris Bundell⁵, hector Chinoy⁶, Claire Coeshott⁷, Charmaine Donald², Juliet Dunphy⁸, Marvin Fritzler⁹, Adrian Heaps², marie Hudson¹⁰, Masataka Kuwana¹¹, Océane Landon-Cardinal¹², Hui Lu¹, FIONNUALA MCMORROW¹, Marie Mayrhofer⁴, Alain Meyer¹³, Birthe Michiels³, Benoit Nespola¹⁴, Susan O'Loughlin¹⁵, Ivana Putova¹⁶, Johan Rönnelid¹⁷, Ross Sadler¹⁸, Maria Teresa Sanz-Martinez¹⁹, Paul Sciore²⁰, Albert Selva-O’Callaghan²¹, Helena Storfors²², Ernesto Trallero-Araguás²³, Yves Troyanov¹², Jade Tyson², Jiří Vencovský²⁴, Akira Yoshida²⁵ and Sarah Tansley¹, ¹University of Bath, Bath, United Kingdom, ²Severn Pathology, North Bristol NHS Trust, Bristol, United Kingdom, ³University Hospitals Leuven, Leuven, Belgium, ⁴MVZ Labor PD Dr. Volkmann und Kollegen GbR, Karlsruhe, Germany, ⁵Department of Clinical Immunology, PathWest Laboratory Medicine, Perth, Western Australia, Australia, ⁶The University of Manchester, Manchester, United Kingdom, ⁷Advanced Diagnostics Laboratories National Jewish Health, Denver, CO, ⁸Royal United Hospital Bath NHS Foundation Trust, Bath, United Kingdom, ⁹Mitogen Diagnostics Corp, Calgary, AB, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹²Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ¹³UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, ¹⁴Laboratoire d’immunologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ¹⁵Greater Manchester Immunology Service, Manchester, England, United Kingdom, ¹⁶Institute of Rheumatology, Prague, Czech Republic, ¹⁷Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ¹⁸Laboratory of Immunology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, England, United Kingdom, ¹⁹Immunology Division, Vall d'Hebron Hospital, Barcelona, Spain, ²⁰Mitogen Diagnostics Corp., Calgary, ²¹Internal Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain, ²²Department of Clinical Immunology and Transfusion Medicine, Uppsala University Hospital, Uppsala, Sweden, ²³Rheumatology Departament, Vall d'Hebron Hospital, Barcelona, Spain, ²⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²⁵Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
Background/Purpose: In idiopathic inflammatory myopathy (IIM) spectrum diseases, myositis-specific and myositis-associated autoantibodies (MSAs/MAAs) are key markers of disease subtype and prognosis and are considered routine…
Abstract Number: 1731 • ACR Convergence 2024
Baricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy: A Randomized, Treatment Delayed-Start Clinical Trial
hector Chinoy¹, Ashma Krishan¹, Yvonne Sylvestre¹, James Lilleker², Patrick Gordon³, Sarah Tansley⁴, Athiveeraramapandian Prabu⁵, Aamir Aslam⁶, Andrew Snedden⁷ and Janine Lamb⁸, ¹The University of Manchester, Manchester, United Kingdom, ²Northern Care Alliance NHS Trust, Salford, United Kingdom, ³nhs, London, United Kingdom, ⁴University of Bath, Bath, United Kingdom, ⁵Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, ⁶Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, ⁸University of Manchester, UK, Manchester, United Kingdom
Background/Purpose: The aim of the study was to assess the effects of baricitinib, a JAK1/2 inhibitor, following 24 weeks of active treatment on disease activity…
Abstract Number: 2670 • ACR Convergence 2024
Sera from Patients with Idiopathic Inflammatory Myopathy Induces Muscle Weakness, Mitochondrial Dysfunction and Induction of Cytokines in Isolated Skeletal Muscle
Cecilia Leijding¹, Suchada Kaewin², Kristofer Andreasson¹, Tomas Schiffer¹, Angeles Galindo-Feria³, Begum Horuluoglu¹, Mattias Carlstrom¹, Stefano Gastaldello¹, Helene Alexanderson⁴, Ingrid Lundberg⁵ and Daniel Andersson⁶, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, ³Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁶Karolinska Institutet, Solna, Sweden
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of systemic autoimmune inflammatory muscle disorders characterized by symmetrical skeletal muscle weakness and accelerated fatigue. Although signs…
Abstract Number: 1139 • ACR Convergence 2024
Comprehensive Single-cell Profiling of Diverse Circulating Immune Cells in Idiopathic Inflammatory Myopathies Identifies a Novel Pathogenic Subset of Monocytes
Shinji Izuka¹, Toshihiko Komai², Hayato Yuuki², Ikuko Ueda³, Manabu Fujimoto⁴, Hiroyuki Fukui⁵, Masaru Takeshita⁶, Natsuka Umezawa⁷, Shinsuke Yasuda⁷, Mitsutaka Yasuda⁸, Yuichiro Fujieda⁹, Tatsuya Atsumi⁹, Takeshi Iwasaki¹⁰, Akio Morinobu¹⁰, Yuya Kondo¹¹, Isao Matsumoto¹¹, Toshio Kawamoto¹², Masakazu Matsushita¹², Naoto Tamura¹³, Taro Iwamoto¹⁴, Hiroshi Nakajima¹⁴, Ken Yoshida¹⁵, Takeo Isozaki¹⁶, Nobuyuki Yajima¹⁶, Keiichi Sakurai¹⁷, Kimito Kawahata¹⁷, Yasuyuki Kamata¹⁸, Kojiro Sato¹⁸, Yoshiya Tanaka¹⁹, Akari Suzuki²⁰, Kazuhiko Yamamoto²¹, Tomohisa Okamura²² and Keishi Fujio², ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan, ³Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Japan, ⁴Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Osaka, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Tokyo, Japan, ⁶Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁷Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Tokyo, Japan, ⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan., Sapporo, Japan, ⁹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ¹⁰Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan, ¹¹Department of Rheumatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Tsukuba, Japan, ¹²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹³Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁴Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan., Chiba, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹⁶Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹⁷Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan., Kawasaki, Japan, ¹⁸Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Tochigi, Japan., Tochigi, Japan, ¹⁹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²⁰Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kanagawa, Japan, ²¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kawasaki, Japan, ²²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan., Bunkyo, Tokyo, Japan
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are heterogeneous diseases, making it crucial to identify distinct pathological processes to improve a treatment strategy. Transcriptomic analyses have revealed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].